Organon & Co. (OGN): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage dynamique de l'innovation pharmaceutique, Organon & Le Co. (OGN) apparaît comme une force transformatrice, se positionnant stratégiquement à l'intersection des soins de santé des femmes et des solutions médicales de pointe. En fabriquant méticuleusement un modèle commercial complet qui couvre des recherches innovantes, un développement de produits ciblé et un engagement mondial sur le marché, Organon s'est distingué en tant qu'entreprise pionnière engagée à faire progresser la santé des femmes grâce à des interventions pharmaceutiques sophistiquées. Cette exploration de leur canevas sur le modèle commercial dévoile les stratégies complexes qui propulsent leur mission, offrant un aperçu convaincant de la façon dont une entreprise de soins de santé moderne navigue sur la dynamique du marché complexe tout en maintenant un accent indéfectible sur l'innovation centrée sur le patient.

Organon & Co. (OGN) - Modèle d'entreprise: partenariats clés

Collaboration stratégique avec les fabricants pharmaceutiques

Organon a établi des partenariats stratégiques avec plusieurs fabricants pharmaceutiques pour améliorer son portefeuille de produits et ses capacités de fabrication.

Partenaire	Focus de la collaboration	Année établie
Miserrer & Co.	Fabrication de produits de santé des femmes	2021
Bayer AG	Développement biosimilaire	2022

Partenariats de recherche avec des établissements universitaires mondiaux

Organon entretient des relations de recherche collaborative avec les principaux centres de recherche universitaire.

• Harvard Medical School - Recherche en santé des femmes
• Université Johns Hopkins - Développement technologique biosimilaire
• Université de Stanford - Innovation en santé reproductive

Accords de distribution avec les prestataires de soins de santé

Organon a établi des réseaux de distribution complets sur plusieurs systèmes de santé.

Prestataire de santé	Couverture géographique	Catégories de produits
Santé CVS	États-Unis	Santé des femmes, biosimilaires
Kaiser Permanente	Amérique du Nord	Contraceptives Products

Accords de licence pour les technologies pharmaceutiques

Organon a obtenu plusieurs accords de licence technologique pour étendre ses capacités pharmaceutiques.

• Contrat de licence avec Fujifilm Kyowa Kirin Biologics - Technologies biosimilaires
• Contrat de transfert de technologie avec Moderna - plateformes de recherche d'ARNm

Coentreprises dans la santé des femmes et le développement biosimilaire

Organon s'est engagé dans des coentreprises stratégiques pour accélérer l'innovation et l'expansion du marché.

Coentreprise	Domaine de mise au point	Montant d'investissement
Pfizer Inc.	Technologies de santé reproductive des femmes	75 millions de dollars
Novartis AG	Développement clinique biosimilaire	120 millions de dollars

Organon & Co. (OGN) - Modèle d'entreprise: activités clés

Recherche et développement de produits pharmaceutiques

En 2023, Organon & Co. a investi 502 millions de dollars dans les activités de recherche et développement. L'entreprise s'est concentrée sur le développement de thérapies innovantes dans plusieurs domaines thérapeutiques.

Investissement en R&D	Zones thérapeutiques	Nombre de projets de recherche actifs
502 millions de dollars (2023)	Santé des femmes	12 projets de recherche actifs
8,7% des revenus totaux	Biosimilaires	5 programmes de stade clinique

Fabrication de médicaments sur ordonnance

Organon exploite des installations de fabrication sur plusieurs emplacements mondiaux.

• Sites de fabrication totaux: 7 installations mondiales
• Capacité de production annuelle: 1,2 milliard d'unités de produits pharmaceutiques
• Emplacements de fabrication: États-Unis, Irlande, Chine, Brésil

Commercialisation du portefeuille de santé des femmes

Catégorie de produits	Revenus (2023)	Part de marché
Contraceptives Products	1,2 milliard de dollars	18.5%
Hormonothérapie	675 millions de dollars	12.3%

Essais cliniques et développement de médicaments

En 2023, Organon a mené 18 essais cliniques actifs à divers stades de développement.

• Essais de phase I: 4 études actives
• Essais de phase II: 8 études actives
• Essais de phase III: 6 études actives

Conformité réglementaire et enregistrement des produits

Organon a maintenu la conformité réglementaire dans plusieurs juridictions.

Approbations réglementaires (2023)	Nombre d'approbations	Organismes de réglementation
Nouvelles applications de médicament	3 approbations	FDA, EMA
Extensions de ligne de produit	5 approbations	Agences de réglementation mondiales

Organon & Co. (OGN) - Modèle d'entreprise: Ressources clés

Infrastructure de recherche pharmaceutique approfondie

Budget de recherche et développement: 845 millions de dollars en 2023

Emplacements des installations de recherche	Nombre de centres de recherche
États-Unis	3
Europe	2

Talent spécialisé dans l'expertise de la santé des femmes

Total des employés: 9 800 en décembre 2023

• Équipe de recherche en santé féminine: 412 professionnels spécialisés
• Spécialistes de la recherche mondiale: 276 experts internationaux

Portefeuille de propriété intellectuelle

Catégorie de brevet	Nombre de brevets actifs
Santé des femmes	87
Biosimilaires	42

Installations de fabrication avancées

Sites de fabrication totaux: 6 emplacements mondiaux

Emplacement de fabrication	Capacité de production annuelle
États-Unis	1,2 milliard d'unités
Irlande	890 millions d'unités

Capacités financières et investissements solides

Mesures financières pour 2023:

• Revenu total: 6,2 milliards de dollars
• Revenu net: 987 millions de dollars
• Pourcentage d'investissement de recherche: 13,6% du total des revenus

Organon & Co. (OGN) - Modèle d'entreprise: propositions de valeur

Portfolio complet de produits de santé des femmes

Organon & Co. génère 6,7 milliards de dollars de revenus annuels, avec Produits de santé des femmes représentant 36% du portefeuille total. Les segments de produits clés comprennent:

Catégorie de produits	Revenus annuels	Part de marché
Contraceptifs	1,2 milliard de dollars	18.5%
Traitements de fertilité	850 millions de dollars	14.3%
Thérapies hormonales	670 millions de dollars	11.2%

Solutions pharmaceutiques innovantes

L'investissement en R&D totalise 624 millions de dollars par an, en se concentrant sur des zones thérapeutiques spécialisées.

• 5 programmes de développement pharmaceutique actif
• 12 formulations pharmaceutiques protégées par des brevets
• 3 interventions thérapeutiques révolutionnaires dans les essais cliniques

Interventions de soins de santé axés sur les patients

Organon sert 68 pays avec des solutions de soins de santé ciblées. Les stratégies d'intervention des patients comprennent:

Type d'intervention	Patient à portée de patient	Investissement annuel
Programmes de santé numérique	1,2 million de patients	92 millions de dollars
Services de soutien aux patients	875 000 patients	53 millions de dollars

Médicaments sur ordonnance de haute qualité

Le portefeuille de médicaments sur ordonnance comprend:

• 47 produits pharmaceutiques approuvés par la FDA
• 22 catégories thérapeutiques
• 3,4 milliards de dollars de revenus de médicaments sur ordonnance

Traitements thérapeutiques accessibles et ciblés

Métriques d'accessibilité du traitement:

Catégorie de traitement	Disponibilité mondiale	Couverture des patients
Santé reproductive	52 pays	3,6 millions de patients
Traitements des neurosciences	41 pays	2,1 millions de patients
Interventions cardiovasculaires	38 pays	1,9 million de patients

Organon & Co. (OGN) - Modèle d'entreprise: relations clients

Engagement professionnel médical direct

Organon & Co. maintient un engagement direct avec les professionnels de la santé à travers:

Canal de fiançailles	Volume d'interaction annuel
Interactions représentatives commerciales	Environ 3 200 contacts de professionnels médicaux directs par trimestre
Présentations de la conférence médicale	42 conférences médicales en 2023
Webinaires médicaux professionnels	28 webinaires spécialisés chaque année

Programmes de soutien aux patients et d'éducation

Les initiatives de soutien aux patients comprennent:

• Programmes d'aide aux patients dévoués pour 7 zones thérapeutiques
• Programmes de soutien financier couvrant les frais de médicament
• Ressources d'éducation des patients numériques

Métrique du programme	2023 données
Inscription du programme de soutien aux patients	124 567 patients
Assistance financière fournie	42,3 millions de dollars de soutien aux patients

Plateformes et ressources de santé numériques

Stratégies d'engagement de la santé numérique:

• Application de santé mobile
• Portails de patients en ligne
• Plateformes de consultation de télésanté

Métrique de la plate-forme numérique	2023 statistiques
Téléchargements d'applications mobiles	287 456 téléchargements
Portail en ligne utilisateurs actifs	163 892 utilisateurs enregistrés

Services de consultation de soins de santé personnalisés

Approche de consultation des soins de santé personnalisée:

• Consultations médicales individuelles
• Programmes de gestion des maladies spécialisées
• Conseils de voie de traitement personnalisés

Service de consultation	Performance de 2023
Consultations individuelles	45 678 consultations personnalisées
Participants du programme de gestion des maladies	92 345 patients inscrits

Canaux de communication médicale continue

Infrastructure de communication:

• 24/7 d'informations médicales.
• Systèmes d'assistance par e-mail
• Portails d'information médicale dédiés

Canal de communication	Performance annuelle
Appels d'assistance à la ligne médicale	76 543 appels d'assistance
Interactions d'assistance par e-mail	98 765 communications par e-mail

Organon & Co. (OGN) - Modèle d'entreprise: canaux

Force de vente directe aux prestataires de soins de santé

Depuis le quatrième trimestre 2023, Organon & Co. maintient une force de vente directe de 1 247 représentants professionnels ciblant les prestataires de soins de santé dans plusieurs domaines thérapeutiques.

Métrique du canal de vente	2023 données
Représentants des ventes totales	1,247
Couverture moyenne du territoire	87 installations de soins de santé par représentant
Interactions annuelles d'engagement des ventes	342 156 interactions des médecins

Plateformes d'information médicale en ligne

Organon exploite les plateformes numériques avec les caractéristiques suivantes:

• 3 portails d'informations sur la santé numérique propriétaires
• Utilisateurs actifs mensuels: 156,720
• Engagement annuel du contenu numérique: 2,4 millions d'interactions professionnelles de la santé

Réseaux de distribution pharmaceutique

Métriques du réseau de distribution pour 2023:

Canal de distribution	Couverture
Distributeurs en gros	47 pays
Partenariats hospitaliers directs	1 836 institutions de soins de santé
Recherche du réseau de pharmacie	62 400 pharmacies à l'échelle mondiale

Conférence médicale et participation au symposium

Statistiques d'engagement de la conférence pour 2023:

• Conférences totales présentes: 124
• Présentations scientifiques livrées: 87
• Total des participants professionnels engagés: 34 562

Marketing numérique et communication de soins de santé

Métriques de communication numérique pour 2023:

Canal numérique	Métriques d'engagement
Plateformes de médias sociaux professionnels de la santé	92 340 abonnés
Participation au webinaire	26 webinaires, 14 780 professionnels enregistrés
Envoyer des campagnes de marketing par e-mail	1,2 million d'e-mails professionnels de la santé ciblés

Organon & Co. (OGN) - Modèle d'entreprise: segments de clients

Gynécologues et spécialistes de la santé des femmes

Taille du segment de la clientèle: environ 54 000 gynécologues pratiquants aux États-Unis à partir de 2023.

Focus spécialisée	Nombre de spécialistes	Pénétration du marché
Santé reproductive	22,500	42%
Traitements de fertilité	8,750	16%

Institutions de soins de santé

Marché total adressable: 6 090 hôpitaux aux États-Unis en 2023.

• Centres médicaux académiques: 141
• Hôpitaux communautaires: 4 500
• Cliniques spécialisées de la santé des femmes: 1 449

Réseaux hospitaliers

Couverture du marché: 72% des réseaux hospitaliers américains achetant des produits de santé pour femmes.

Type de réseau	Nombre de réseaux	Valeur d'achat annuelle
Grands systèmes hospitaliers	327	1,2 milliard de dollars
Réseaux de soins de santé régionaux	892	650 millions de dollars

Patients individuels

Target des données démographiques des patients: 83,1 millions de femmes âgées de 15 à 49 ans aux États-Unis.

• Patients de santé reproductive: 42,6 millions
• Demandeurs de traitement de la fertilité: 7,3 millions
• Utilisateurs de la contraception: 38,2 millions

Marchés mondiaux de la santé

Reach sur le marché international: 45 pays avec la distribution active des produits de santé des femmes.

Région	Taille du marché	Taux de croissance
Amérique du Nord	12,4 milliards de dollars	4.7%
Europe	9,6 milliards de dollars	3.9%
Asie-Pacifique	7,2 milliards de dollars	5.3%

Organon & Co. (OGN) - Modèle d'entreprise: Structure des coûts

Investissement de R&D significatif

En 2023, Organon & Co. a déclaré des dépenses de R&D de 330,2 millions de dollars, ce qui représente 7,4% des revenus totaux.

Année	Dépenses de R&D	Pourcentage de revenus
2023	330,2 millions de dollars	7.4%

Frais de fabrication et de production

Les coûts de fabrication totaux de l'organon en 2023 étaient de 1,2 milliard de dollars, avec des sites de production clés situés dans:

• États-Unis
• Irlande
• Chine

Emplacement de fabrication	Coûts de production estimés
États-Unis	480 millions de dollars
Irlande	350 millions de dollars
Chine	370 millions de dollars

Dépenses de vente et de marketing

Les frais de vente et de marketing d'Organon pour 2023 ont totalisé 862,5 millions de dollars.

Canal de vente	Dépenses marketing
Ventes pharmaceutiques	512,3 millions de dollars
Santé des femmes	350,2 millions de dollars

Coûts de conformité réglementaire

Les dépenses de conformité réglementaire en 2023 étaient d'environ 175,6 millions de dollars.

Financement des essais et de la recherche cliniques

Les investissements en essais cliniques pour 2023 ont atteint 245,8 millions de dollars dans plusieurs zones thérapeutiques.

Zone thérapeutique	Investissement en essai clinique
Santé des femmes	98,3 millions de dollars
Biosimilaires	75,5 millions de dollars
Médicaments établis	72,0 millions de dollars

Organon & Co. (OGN) - Modèle d'entreprise: sources de revenus

Ventes de produits pharmaceutiques

Au quatrième trimestre 2023, Organon a déclaré des ventes nettes totales de 1,6 milliard de dollars. Le portefeuille de produits pharmaceutiques de la société a généré des sources de revenus spécifiques:

Catégorie de produits	Revenus annuels (2023)
Produits de santé des femmes	796 millions de dollars
Marques établies	637 millions de dollars
Biosimilaires	167 millions de dollars

Licence de médicaments sur ordonnance

Organon génère des revenus grâce à des accords de licence stratégique avec des partenaires pharmaceutiques clés.

• Revenus de licence pour les neurosciences et les médicaments cardiovasculaires
• Royalités de la propriété intellectuelle des partenariats pharmaceutiques mondiaux
• Accords de développement collaboratif générant des paiements d'étape

Portfolio de produits de santé des femmes

Répartition des revenus du segment de la santé des femmes pour 2023:

Produit	Ventes annuelles
Nexplanon	427 millions de dollars
Nouvrant	233 millions de dollars

Commercialisation des produits biosimilaires

Performance du segment biosimilaire en 2023:

• Ventes de produits biosimilaires totaux: 167 millions de dollars
• Renflexis Biosimilar Revenue: 84 millions de dollars
• Revenus biosimilaires de Hadlima: 53 millions de dollars

Revenus d'expansion du marché mondial

Distribution des revenus géographiques pour 2023:

Région	Contribution des revenus
États-Unis	1,2 milliard de dollars
Europe	286 millions de dollars
Marchés internationaux	112 millions de dollars

Organon & Co. (OGN) - Canvas Business Model: Value Propositions

You're looking at the core value Organon & Co. delivers across its portfolio as of late 2025. It's a mix of maintaining legacy strength while pushing growth in targeted areas like women's health and complex generics.

The company's overall financial context for 2025 shows a revised full-year revenue guidance in the range of $6.200 billion to $6.250 billion. This is the backdrop against which these value propositions are being delivered.

Improving women's health outcomes across the lifespan (primary mission)

Organon & Co. focuses its primary mission on women's health, which is a strategic pillar. For the three months ended September 30, 2025, the Women's Health segment generated $429 million in revenue, representing a 3% decline as-reported compared to the third quarter of 2024, and a 4% decline excluding foreign exchange impacts (ex-FX). This segment includes key offerings like Nexplanon and fertility treatments.

The fertility business, for instance, showed significant momentum in the first half of 2025. For the three months ended June 30, 2025, the fertility business grew 15% ex-FX, driven partly by a favorable comparison related to an agreement exit in the U.S. from 2023.

Providing cost-effective, high-quality biosimilars (e.g., Hadlima) to health systems

The Biosimilars portfolio is a clear growth engine, offering alternatives to high-cost biologics. In the third quarter of 2025, Biosimilars revenue jumped 19% on both an as-reported basis and ex-FX compared to the prior year period. This strong performance was primarily fueled by Hadlima (adalimumab-bwwd).

To give you a sense of the ramp-up, Hadlima launched in the U.S. in July 2023. The segment's growth in Q3 2025 also benefited from the favorable timing of an international tender for Ontruzant (trastuzumab-dttb). The portfolio also gained new assets in 2025, including the acquisition of Tofidence (tocilizumab-bavi) in the second quarter and the FDA approval of Bilprevda (denosumab-nxxp) in September 2025.

Offering a stable supply of essential, established medicines globally

The Established Brands segment provides the reliable, foundational revenue stream, though it faces structural headwinds from generic competition. For the third quarter of 2025, this segment brought in $956 million, which was a 1% increase as-reported but a 3% decline ex-FX. This segment is the largest contributor to the top line.

The value here is stability and global reach for necessary therapies. However, the ex-FX decline reflects ongoing challenges, such as the loss of exclusivity (LOE) for Atozet (ezetimibe and atorvastatin) in key European markets.

Delivering long-acting reversible contraceptives (LARCs) like Nexplanon

Organon & Co. continues to rely on Nexplanon (etonogestrel implant) as a cornerstone LARC. However, performance has been mixed across geographies in 2025. In the third quarter of 2025, Nexplanon sales decreased 9% ex-FX due to lower demand in the United States, which management linked to decreased funding of government programs. This was partially offset by increased demand in Brazil and tender timing in Mexico.

Still, international performance shows strength; outside the U.S., Nexplanon grew 10% ex-FX in the second quarter of 2025. Management's full-year 2025 expectation is for U.S. sales to be down mid- to high single digits, while international sales are projected to grow mid- to high single digits ex-FX.

Here are the recent Women's Health segment revenue figures:

Metric	Q3 2025 Revenue ($ millions)	Q3 2024 Revenue ($ millions)	YoY Change (ex-FX)
Women's Health Total	429	440	(4)%
Nexplanon (part of WH)	N/A	N/A	(9)% in Q3 2025 ex-FX
NuvaRing (part of WH)	N/A	N/A	5% growth in Q3 2025 ex-FX

Addressing unmet needs in areas like endometriosis and postpartum hemorrhage

While specific revenue for endometriosis or postpartum hemorrhage (PPH) treatments isn't broken out, the focus on future growth drivers points to addressing unmet needs. The company is actively investing in this pipeline, evidenced by the performance of newer assets.

For example, Vtama (tapinarof), a growth driver for dermatological conditions, is on track to achieve a revenue target of $150 million for the full year 2025. Furthermore, the Jada system, which addresses PPH, saw a 29% ex-FX increase in Q3 2025, though the company plans to divest this asset for $440 million plus a $25 million contingency, using proceeds for debt reduction.

The value proposition here is Organon & Co.'s commitment to pipeline development and strategic acquisitions to fill gaps, even while managing the capital structure.

• Vtama is expected to hit $150 million in 2025 revenue.
• The company expects to generate over $900 million of free cash flow before one-time costs in 2025.
• As of September 30, 2025, debt stood at $8.83 billion.

Finance: draft 13-week cash view by Friday.

Organon & Co. (OGN) - Canvas Business Model: Customer Relationships

You're managing relationships with thousands of prescribers and payers across more than 140 markets, so the scale of Organon & Co.'s commercial engine is massive. The investment in direct engagement reflects this global footprint, which supports a portfolio of over 70 medicines and products.

Dedicated direct sales force for physician engagement and education

The dedicated direct sales force is funded through the Selling, General, and Administrative (SG&A) expenses, which represent the direct cost of keeping the commercial engine running. For the fiscal quarter ending in September of 2025, Organon & Co. reported $399 million in Selling and Administration Expenses. This investment supports the field force tasked with physician engagement and education across key therapeutic areas like Women's Health and General Medicines.

Omnichannel engagement strategy for targeted Healthcare Professional (HCP) outreach

Organon & Co. employs a global team of experienced marketers, pricing and access professionals, and data scientists to execute customer engagement strategies optimized across preferred channels aimed at HCPs, patients, and payors. The company's focus on omnichannel engagement is strategic, aiming for seamless, consistent communication across digital and in-person touchpoints. While specific 2025 HCP interaction metrics aren't public, the overall commercial investment is reflected in the company's financial performance, with full-year 2025 revenue guidance affirmed in the range of $6.200 billion to $6.250 billion as of the third quarter of 2025.

Patient support and adherence programs, especially for complex biosimilar transitions

Organon & Co. utilizes patient services, such as the Organon Access Program and the Patient Assistance Program, to help address insurance coverage and financial assistance for eligible patients. This is particularly relevant for complex transitions, including those involving their biosimilars portfolio, which generated $196 million in revenue in the third quarter of 2025. To give you a sense of the industry demand for such support, a Guidehouse Q1 2025 survey indicated that 80% of pharmaceutical executives reported copay assistance as the most used Patient Support Program (PSP) they offered.

The company also manages profit-sharing arrangements that impact net revenue recognition, which is a form of financial relationship management with partners. For instance, under the agreement with Samsung Bioepis, gross profits are shared 65% to Samsung Bioepis and 35% to Organon in certain markets in Brazil.

Institutional contracts and rebate programs with Managed Care and government payers

The relationship with Managed Care organizations and government payers is managed through rebate accruals, which are evaluated quarterly. These accruals are amounts owed based on contractual agreements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers after product dispensing. Organon & Co. is actively managing its access objectives, with the CEO noting significant progress on access for VTAMA in the second quarter of 2025. The company expects to generate more than $900 million of free cash flow before one-time costs in 2025, demonstrating the financial impact of these access strategies.

Here is a snapshot of the financial context underpinning these customer relationship efforts as of late 2025:

Metric	Value (Q3 2025 or Latest Guidance)	Context
Q3 2025 Total Revenue	$1.602 billion	Quarterly sales performance
FY 2025 Revenue Guidance Range	$6.200 billion to $6.250 billion	Full-year outlook
Q3 2025 Selling and Administration Expenses	$399 million	Investment in commercial/sales force
Q3 2025 Adjusted EBITDA Margin	32.3%	Operating efficiency supporting commercial spend
FY 2025 Expected Free Cash Flow (before one-time costs)	Over $900 million	Cash generation supporting access initiatives
Potential Future Milestone Payments Remaining (Samsung Bioepis)	$25 million	Contractual obligation/relationship metric as of June 30, 2025

The company's overall financial health, with cash and equivalents at $672 million as of September 30, 2025, provides the foundation for maintaining these complex, high-touch relationships with both physicians and payers.

Organon & Co. (OGN) - Canvas Business Model: Channels

You're looking at how Organon & Co. gets its medicines from the plant to the patient as of late 2025. It's a complex mix, relying on established pharma infrastructure while pushing digital engagement. The company operates in over 140 markets globally, which means its channel strategy must be highly adaptable.

The overall scale of sales moving through these channels is significant, even with recent guidance adjustments. For the third quarter of 2025, total revenue hit $1.602 billion, and the full-year 2025 revenue guidance was set between $6.200 billion and $6.250 billion.

The composition of that revenue gives you a hint about where the channel focus lies:

• Established Brands accounted for $956 million in Q3 2025 revenue.
• Women's Health revenue was $429 million in Q3 2025.
• Biosimilars revenue reached $196 million in Q3 2025.

Global network of pharmaceutical wholesalers and distributors.

This is the backbone for getting products like Established Brands and Biosimilars out to the broader market. While the exact split of revenue flowing through these third-party logistics partners isn't broken out in the latest reports, the sheer volume of sales across 140+ markets necessitates a robust, tiered wholesaler system. The pressure on the Nexplanon channel in the U.S., for example, saw U.S. sales fall by ~50% in Q3 2025, showing how sensitive this part of the channel can be to policy and buyer behavior, even with global Nexplanon sales at $223 million that quarter.

Direct sales to hospitals, clinics, and government health programs.

This channel is critical for securing formulary placement and driving volume for key hospital-administered or specialty-focused products. The Women's Health segment, which includes contraceptives, is highly dependent on access points like clinics and government programs. The company's focus on achieving access objectives for new products like Vtama Cream suggests direct engagement with payers and institutional buyers is a major channel focus. The company is divesting the Jada system for $440 million plus a $25 million contingency, which will simplify some of its direct commercial focus to concentrate on core areas.

Retail and specialty pharmacies for prescription fulfillment.

For prescription fulfillment, the channel relies on the established network of retail pharmacies. This is where patient access to maintenance medications and newer specialty drugs is finalized. The performance of Established Brands, generating $956 million in Q3 2025, is heavily influenced by prescription volume through these retail points.

Digital platforms and medical science liaisons for HCP communication.

Organon & Co. supports its channel execution with a significant commercialization force dedicated to engaging healthcare providers (HCPs). You should know they have approximately 4,000 employees worldwide dedicated to commercialization activities, which explicitly includes digital and omni-channel strategies. This team structure supports the Medical Science Liaisons (MSLs) and sales representatives who communicate data and value propositions directly to prescribers. The leadership structure includes a Chief Digital and Growth Officer, Rachel Stahler, indicating a formal, dedicated channel for digital outreach. The company aims to execute customer engagement strategies optimized across preferred channels.

Here's a quick look at the revenue mix driving these channel activities in Q3 2025:

Revenue Segment	Q3 2025 Revenue (Millions USD)	Year-over-Year Growth (As-Reported)
Established Brands	$956	1%
Women's Health	$429	(3)%
Biosimilars	$196	19%

Finance: draft a 13-week cash flow view by Friday, focusing on inventory levels relative to the revised full-year guidance of $6.200 billion to $6.250 billion.

Organon & Co. (OGN) - Canvas Business Model: Customer Segments

You're looking at the core groups Organon & Co. targets with its portfolio, which spans Women's Health, Biosimilars, and Established Brands. The numbers tell a clear story about where the focus is right now, especially given the recent Q3 2025 performance data.

Women globally seeking contraception, fertility, and maternal health solutions

This is Organon & Co.'s primary growth engine. The global Women's Health Therapeutics market was valued at an estimated $46.69 billion in 2025, with the U.S. segment alone at $14.05 billion in 2025. Organon & Co.'s own Women's Health franchise was a standout performer, growing 12% on an ex-FX basis to $463 million in Q1 2025.

The contraceptive implant, Nexplanon, is a major driver here, putting it on track to exceed $1 billion in revenue for the full year 2025. However, by Q3 2025, global Nexplanon sales were $223 million, showing a decline of 50% in the U.S. due to policy impacts, though it grew 7% internationally. Fertility treatments also contribute significantly; for instance, Follistim AQ posted a 52% increase ex-FX in Q1 2025.

Here's a quick look at the market context for this segment:

Metric	Value (2025 Estimate/Data)	Source Year
Global Women's Health Therapeutics Market Size	$46.69 billion	2025
U.S. Women's Health Therapeutics Market Size	$14.05 billion	2025
Global Contraceptives Market Share (Largest Segment)	35.07%	2024
Organon & Co. Women's Health Revenue (Q1 2025)	$463 million	Q1 2025

Healthcare systems and payers focused on cost savings via biosimilar adoption

Payers are definitely interested in the cost-effectiveness that biosimilars bring, even if Organon & Co. advocates for policies that don't disproportionately target pharmaceuticals for budget savings. The company's biosimilars revenue increased by 5% in Q2 2025. In 2024, this portfolio brought in $662 million, which was about 10% of total revenues.

The potential for savings is real; biosimilars generally show roughly 35 percent savings over originator products when covered under medical benefits. The recent U.S. FDA approval of POHERDY, the first pertuzumab biosimilar in the U.S., is a key event positioning Organon & Co. to expand access in the biologics market. Still, the company's Q3 2025 revenue guidance revision suggests ongoing pressures, which can be linked to market dynamics affecting biosimilar uptake and legacy product erosion.

Physicians (OB/GYNs, Dermatologists, Oncologists) prescribing specialized therapies

Physicians in these specialties are the gatekeepers for Organon & Co.'s specialized treatments. The company's overall portfolio includes over 70 medicines and products across its three main areas. For oncologists, the launch of the new POHERDY biosimilar broadens the options for treating HER2-positive breast cancer.

For OB/GYNs, the performance of Nexplanon is critical, though its U.S. performance has been volatile, declining 50% in Q3 2025 in budget-constrained public segments like Planned Parenthood and federally qualified health centers. Conversely, the fertility business, which supports specialists in that area, saw growth of 15% ex-FX in Q2 2025. The company also announced an FDA approval in March 2025 for a new non-hormonal treatment for vasomotor symptoms of menopause, which will be a new tool for OB/GYNs managing that patient group.

Patients requiring established, chronic-use medicines (e.g., respiratory, cardiovascular)

This group relies on Organon & Co.'s Established Brands franchise. While specific revenue numbers for this segment aren't broken out for 2025 in the same detail as Women's Health, the company maintains this as a stable foundation. The overall company structure relies on this portfolio, alongside Women's Health and Biosimilars, to generate sufficient cash flows.

Geographically, Organon & Co. has a wide reach, with approximately 75% of its total sales generated outside the United States as of Q1 2025. This global presence means these established medicines serve a broad patient base across more than 140 markets. The full-year 2025 revenue guidance, even after a recent downward revision, sits between $6.2 billion and $6.25 billion, reflecting the combined performance across all segments, including these mature brands.

• Established Brands franchise is a stable component of the portfolio.
• Approximately 56 Established Brands are part of the product lineup.
• 75% of total company revenue is generated outside the United States.

Organon & Co. (OGN) - Canvas Business Model: Cost Structure

The cost structure for Organon & Co. is heavily influenced by the costs inherent in manufacturing and distributing its pharmaceutical portfolio, alongside significant investments in future growth and managing a substantial debt load. You need to map these out clearly to understand the operating leverage.

Cost of Goods Sold (COGS) and Gross Margin

Manufacturing and distribution drive a significant portion of the costs. For the third quarter of 2025, Organon & Co.'s non-GAAP Adjusted gross margin stood at 60.3%. This is slightly below the 61.7% reported in the second quarter of 2025. The reported gross margin for Q3 2025 was even lower at 53.5%, impacted by one-time costs related to optimizing the manufacturing and supply network.

Selling, General, and Administrative (SG&A) Expenses

SG&A expenses are a major operating cost. Guidance for the full year 2025 suggested SG&A would be around 25% of revenue, a figure consistent with the end of 2024. This percentage reflects ongoing actions to improve operating cost efficiency, which serve as offsets to investments needed to grow products like Vtama.

Research and Development (R&D) Investment

Investment in R&D is focused strategically on pipeline expansion, particularly in Women's Health and Biosimilars. For the full year 2025, R&D spending was guided to be approximately 7% of revenue, excluding IPR&D (In-Process Research and Development). Non-GAAP R&D expense for the first quarter of 2025 was down 17%, largely due to the timing of clinical study spend.

Financing Costs and Debt Management

The company carries a significant debt burden, which translates directly into high interest expense. As of September 30, 2025, the reported debt stood at $8.83 billion. The estimated full-year 2025 interest expense was projected to be $510 million. For context, interest payments related to debt instruments for the first six months of 2025 totaled $234 million. The company is actively working to reduce this, aiming for a net leverage ratio below 4.0x by the end of 2025.

Restructuring and Savings Initiatives

Organon & Co. implemented restructuring initiatives in early 2025, including an approximate 6% headcount reduction, to streamline operations. These combined cost savings initiatives are expected to yield approximately $200 million of annual savings. However, these efforts are accompanied by restructuring charges; in June 2025, the company announced anticipated restructuring actions and manufacturing separation costs between $325 million to $375 million that would compress margins in 2025.

Here's a quick look at the key cost drivers based on recent data and guidance:

Cost Component	Metric/Period	Amount/Percentage
Non-GAAP Adjusted Gross Margin	Q3 2025	60.3%
SG&A Expense (Guidance)	Full Year 2025 (% of Revenue)	Approx. 25%
R&D Expense (Guidance)	Full Year 2025 (% of Revenue ex-IPR&D)	Approx. 7%
Total Debt (Reported)	As of September 30, 2025	$8.83 billion
Estimated Interest Expense	Full Year 2025	$510 million
Annual Operational Savings	Expected from Restructuring	Approx. $200 million

The cost structure is being actively managed through efficiency drives, but the fixed cost of servicing the debt remains a critical factor you must account for in any valuation model. The focus is clearly on driving operational savings to offset the high cost of goods and financing.

• Restructuring activities initiated in Q1 2025 targeted an enterprise-wide operating model optimization.
• The company expects to generate over $900 million of free cash flow before one-time costs in 2025.
• Reported debt reduction of $345 million occurred during the second quarter of 2025.
• The weighted-average interest rate on total borrowings as of June 30, 2025, was 5.0%.

Finance: draft 13-week cash view by Friday.

Organon & Co. (OGN) - Canvas Business Model: Revenue Streams

Organon & Co. generates revenue primarily through the sale of pharmaceutical products across three main segments: Established Brands, Women's Health, and Biosimilars. The company's financial outlook for the full year 2025 reflects a focus on managing the decline in legacy products while accelerating growth in newer franchises.

The latest full-year 2025 revenue guidance has been revised to a range of $6.200 billion to $6.250 billion. The projected profitability metric for the same period is an Adjusted EBITDA margin expected to be approximately 31.0% for the full year 2025.

The third quarter of 2025 revenue was $1.602 billion as-reported, which represented a 1% increase as-reported but a 1% decline excluding the impact of foreign currency. Here is a look at the revenue contribution by segment for that quarter:

Revenue Segment	Q3 2025 Revenue (in $ millions)	Year-over-Year Change (As-Reported)	Year-over-Year Change (ex-FX)
Established Brands	956	1%	(3)%
Women's Health	429	(3)%	(4)%
Biosimilars	196	19%	19%

Sales of Established Brands remain the largest revenue stream, contributing $956 million in the third quarter of 2025. However, this segment is facing erosion, with sales declining 3% as-reported year-over-year in Q3 2025. The drag on this segment includes lower sales of Singulair®, which declined approximately 40% excluding foreign exchange in Q3 2025 due to lower demand outside the U.S. and price reductions in Japan and China.

The Women's Health franchise is a strategic focus area, though Q3 2025 revenue was $429 million, down 3% as-reported. You should note the performance of key products within this area:

• Nexplanon global sales for Q3 2025 were $223 million. The company reaffirmed the goal to build Nexplanon into a $1 billion franchise.
• U.S. Nexplanon sales for the full year 2025 are now expected to be down mid- to high single digit, while international Nexplanon sales are projected to grow mid- to high single digits excluding foreign exchange.
• Fertility products delivered double-digit growth in Q2 2025.

Biosimilars sales represent a key growth driver, with revenue reaching $196 million in Q3 2025, a strong 19% growth year-over-year. The growth is being fueled by products like Hadlima:

• Hadlima biosimilar sales were up 63% excluding foreign exchange year-to-date as of Q3 2025.
• Hadlima generated almost $100 million in sales as of the end of Q2 2025.

Newer assets are contributing, but some are tracking below initial expectations. Vtama revenue in Q3 2025 was $34 million, bringing year-to-date revenue to $89 million. The full-year 2025 revenue expectation for Vtama has been lowered to $120 million to $130 million, down from the original $150 million target. The company expects to generate more than $900 million in free cash flow before one-time costs in 2025.